Aleta Biotherapeutics (Aleta), a clinical stage, immuno-oncology company with a CAR T-cell engager (CTE) platform that enables cell cancer therapies to work more effectively, and Cancer Research UK’s Centre for Drug Development, today announce the first patient was dosed in a Phase 1/2 clinical trial. This trial is evaluating the Company’s first-in-class biologic CAR T-cell engager, ALETA-001, for the treatment of patients with B-cell malignancies who are relapsed/refractory to CD19-targeting CAR T-cell therapy.
Cancer Research UK’s Centre for Drug Development is sponsoring and conducting…
Biocair, an award-winning life science logistics expert, is pleased to announce the opening of its office in Bangalore, the company’s fourth office in India. Spread over 2500 square feet, the new office was inaugurated by Neha Naik, General Manager Biocair India, on February 13 alongside key customers and key partners. Biocair first established operations in the country in 2021 with its corporate office in Mumbai and other locations in New Delhi and Chennai.
Ms. Naik comments “The pharma business in India is worth approximately $50 billion and is expected to reach $100 billion by 2030 - we…
• Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases
• Targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year
OXFORD, UK and SALT LAKE CITY, US – 15 February 2024 – The pioneering precision medicine company, PrecisionLife, and leading US multi-specialty healthcare center, Metrodora Institute, are co-investing in a first-of-its-kind partnership to jumpstart the diagnosis and treatment options for a range of complex, chronic…
We recently conducted a survey to help us and the businesses we represent better understand the future of recruitment.
In light of the enduring challenges posed by the cost of living crisis for both job seekers and organisations, our goal was to collect valuable data. We hope this information empowers businesses to make informed decisions and shape effective recruitment strategies, aiding their success in a volatile market, not only for 2024 but for the years ahead.
Summary of findings:
Our survey results illuminate the landscape for 2024, offering insights into both hurdles and potential…
Following the success of three previous events of a similar format, the Anglia Innovation Partnership (AIP) team, the science park management company, at Norwich Research Park will continue to hold enterprise showcase events throughout 2024 to demonstrate the strength of enterprise, innovation, research and collaboration across the campus that has been delivered through the ongoing campus-wide enterprise strategy.
The previous event held in November 2023 organised in collaboration with the UEA and Royal Society Entrepreneur in Residence, was an enormous success, with an exciting format…
Expanded solutions for seamless stem cell research
AMSBIO, a leading provider of innovative products and services for the life sciences community, announces the launch of its Expanded Stem Cell Synergy Solutions.
Over the last two decades AMSBIO has established itself as a leading international supplier of solutions for streamlined and efficient ES/iPS Cell Culture using feeder-free StemFit® media and iMatrix recombinant laminin extracellular matrices. Backed by knowledgeable support teams in the UK, USA, and Germany – AMSBIO has expanded its products and services across the entire stem cell…
In October 2023, the Financial Reporting Council (FRC) announced a delay to the publication and effective date of the future changes to UK GAAP from its periodic review.
The revised suite of standards reflecting the second periodic review of UK GAAP is now expected to be issued in the first half of 2024 and implemented not before periods commencing on or after 1 January 2026, instead of 1 January 2025 as originally planned.
Understanding the delay
The delayed issue date has provided the FRC with more time as it considers over 50 responses to its consultation on the…
Kadans Science Partner adds to Oxfordshire’s laboratory supply with the completion of Barton House
Owned and developed by Kadans Science Partner, the brand new, purpose built laboratory accommodation is designed to a highly technical specification, including an on-site café, cycle storage and EV charging points.
London, 12 February 2024 – Barton House, located on Abingdon Science Park, is the latest purpose-built laboratory facility to come to the market in Oxfordshire. Kadans Science Partner (“Kadans”) continues to expand this established cluster of innovative businesses on Abingdon…
• Key deals cause a surge in Golden Triangle leasing activity, bolstered by the 352,000 sq ft transacted in final quarter of last year
• Development pipeline totals 3.1 million sq ft across Golden Triangle
Demand for life sciences space in the ‘Golden Triangle’ surged in 2023, with the 925,000 sq ft of space representing the highest annual volume since 2015, according to the latest figures from Cushman & Wakefield.
Take up of laboratory space was bolstered by a robust final quarter, with 352,000 sq ft transacting equating to more than double Q3 and the five-year average. Activity in Q4…
Pioneer Group, a leading developer and operator of life science and high-tech campuses, has secured planning permission from Cambridge City Council, subject to S106, for the redevelopment of the Grafton Centre in the city.
The Planning Committee at Cambridge City Council yesterday (7 Feb) voted in favour of the multi-million-pound regeneration for the shopping centre, which will be converted into laboratory and office space for life science and tech companies. The western end of the centre will be retained and transformed into a more attractive destination for local shoppers.
The…